InSphero has acquired Doppl SA for an undisclosed amount, a strategic purchase designed to significantly expand InSphero’s capabilities in advanced biological models for drug discovery and personalized medicine. Doppl SA is a leader in engineering industry-standard organoids for disease modeling and personalized medicine, engaging in partnered projects to provide relevant, high-quality, and scalable organoid models crucial for preclinical drug development. This transaction involves the outright acquisition of Doppl SA's operations and intellectual property, distinct from a capital raise or funding round.
Doppl SA's specialized expertise encompasses a suite of vital services for drug developers. These include compound profiling for toxicity screening, utilizing established models of human healthy gastro-intestinal organoids, and screening for epithelial fluid transport. Furthermore, Doppl excels in the development of customized organoid lines that accurately model specific tissues or diseases of interest. Its advanced models are widely applied across critical research areas such as oncology, inflammatory diseases, rare diseases, immuno-oncology, and ADME-Tox studies. The integration of Doppl’s innovative platforms and its vision for a global, crowd-sourced bio-base of biological samples is expected to enhance InSphero’s service offerings and accelerate research across these therapeutic fields.
The strategic rationale for this acquisition is to combine InSphero’s existing strengths with Doppl’s highly specialized organoid engineering and preclinical services. Synergies are anticipated through an expanded portfolio of high-fidelity disease models and a broader range of comprehensive screening capabilities, allowing for more accurate and efficient drug discovery and development. This move is set to strengthen InSphero’s market position in advanced in vitro models, providing pharmaceutical and biotech clients with enhanced tools. The combined entity is well-positioned to accelerate innovation in drug development and deliver more effective personalized medicine solutions globally.